Company Analysis
Sign in

XTL Biopharmaceuticals Ltd. (XTLB)

Nasdaq: XTLB · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2004
Full chart Alerts Compare
Grade4.6
◀ Past 5.8● Present 4.3▶ Future 4.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2024, as filed
Revenue$451,000
Net income-$1.0M+42.4%
Earnings per share$-0.000.0%
Operating cash flow-$1.6M-128.9%
Cash$371,000-73.5%
Debt$138,000
Shareholders’ equity$5.4M+144.8%
Shares, diluted673.0M+23.5%
Return on equity-18.9%
The recordfrom its filings
Filings in 202625
Newest filingOct 14 · 6-K
Annual reportJun 30, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted9
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
15161718192021222324
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton XTLB · research, not advice